Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age 18-80 years, male or female
2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
3. Splenomegaly and hypersplenism
4. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )
5. Child-Pugh Class A or B liver function
6. Signed written informed consent
7. Ability to complete 24-month follow-up
Exclusion Criteria:
1. Child-Pugh Class C liver cirrhosis
2. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection
3. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders
4. Metabolic/endocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.
5. Infections/inflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases.
6. Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery
7. Pregnancy or lactation
8. Poor compliance, inability to complete follow-up
Primary outcome measure(s)
Total cholesterol (TC) level — at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24 Change in total cholesterol (TC) level
Total triglycerides (TG) level — at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24 Change in total triglycerides (TG) level
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.